Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment
- 1 July 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 12 (4) , 368-377
- https://doi.org/10.1097/00001622-200007000-00015
Abstract
Neuroendocrine tumors include carcinoids and pancreatic endocrine tumors, which share a number of common features in their pathology, ability to cause clinical symptoms due to ectopic hormone and bioamine release, localization methods, and treatment. Although generally slow growing, a proportion demonstrate aggressive tumor growth. Therefore, in many cases treatment must be directed against both the tumor and the hormone-excess state. There have been significant recent advances into their molecular pathogenesis, natural history, and prognostic factors; clinical presentation defined by larger series analysis; localization methods; and the development of new treatments directed against the tumor and to control the hormone-excess state (including depot somatostatin analogues, interferon combinations, embolization, chemoembolization, radiotherapy with novel somatostatin analogues, and liver transplantation). Recent advances in each of these areas are briefly discussed.Keywords
This publication has 66 references indexed in Scilit:
- Surgery to Cure the Zollinger–Ellison SyndromeNew England Journal of Medicine, 1999
- Surgery for the Zollinger–Ellison SyndromeNew England Journal of Medicine, 1999
- Treatment with High Dose [111In-DTPA-D-PHE1]-Octreotide in Patients with Neuroendocrine Tumors: Evaluation of Therapeutic and Toxic EffectsActa Oncologica, 1999
- Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumoursNuclear Medicine Communications, 1998
- The Cost-Effectiveness of Octreotide Acetate in the Treatment of Carcinoid Syndrome and VipomaInternational Journal of Technology Assessment in Health Care, 1998
- Octreotide Long-Acting Release (LAR)Drugs, 1997
- Carcinoids of the jejunum and ileumCancer, 1997
- Induction of Apoptosis in Neuroendocrine Tumors of the Digestive System During Treatment with Somatostatin AnalogsActa Oncologica, 1997
- The Use of New Somatostatin Analogues, Lanreotide and Octastatin, in Neuroendocrine Gastro-lntestinal TumoursDigestion, 1996
- The Clinical Use of Interferons in the Management of Neuroendocrine Gastroenteropancreatic TumorsAnnals of the New York Academy of Sciences, 1994